Health Technology Assessment
Health Technology Assessment (HTA) is designed to support the process of decision-making in health care at policy level by providing reliable information. HTA has been compared to a bridge between the world of research and the world of decision-making.
HTA involves a comprehensive evaluation of the clinical effectiveness, cost-effectiveness, and the ethical, legal, and social implications of health technologies on patient health and the health care system.
We are currently in the middle of the HTA process as part of the Drug Approval Process of Trikafta. This is part of the aligned review of Trikafta. This means that the manufacturer is seeking a Notice of Compliance (Health Canada regulatory approval) and coverage recommendations at the same time through the Health Technology Assessment process.
They will be reviewing the safety and efficacy of Trikafta at the same time as giving it a rating that will help the provinces determine how/if they will fund the medicine. We expect them to release their findings shortly after Health Canada’s regulatory review which can take a maximum of 180 days. Following regulatory approval and an HTA recommendation, the pCPA will negotiate with Vertex and produce a letter of intent to list (LOI). Following pCPA, each individual province will then decide if and to what degree they will fund this life-saving medicine.
If you or a family member is waiting for Trikafta, you are critical in this stage of the fight. If your life was saved as a result of compassionate care and you are currently prescribed Trikafta, we want to hear your story of success. This will aid us in creating a submission to CADTH and INESSS on behalf of CF patients and their support systems.
Stay in the loop on our social channels:
There will be one submission to CADTH on behalf of this movement and there will be an opportunity for all patients’ voices to be heard in our INESS submission initiative.
Key Dates:
CADTH Submssion February 12, 2021
INESS Submission: February 24, 2021
BC Pharmacare: TBD
Stay tuned for more details.
To learn more about Health Technology Assessments, CADTH, and INESSS by exploring the following links:
CADTH Open Calls for Patient and Clinician Input Trikfata
CADTH: About the Health Technology Assessment Service
ICER Reports:
ICER: An assessment of Vertex's CFTR modulators: Symdeko, Orkambi, Kalydeco, and Trikafta.
ICER Issues Final Report and Policy Recommendations on Treatments for Cystic Fibrosis
Report-at-a-glance: https://tinyurl.com/y2gy3vye
Final Evidence Report: https://tinyurl.com/y6s7qskh
Scholarly Articles on Health Technology Assessments in Canada:
Priority setting for health technology assessment at CADTH
Husereau, Don; Boucher, Michel; Noorani, Hussein. International Journal of Technology Assessment in Health Care; Cambridge Vol. 26, Iss. 3, (Jul 2010): 341-7. DOI:10.1017/S0266462310000383
Patients’ perspectives can be integrated in health technology assessments: an exploratory analysis of CADTH Common Drug Review
Berglas, S., Jutai, L., MacKean, G. et al. Patients’ perspectives can be integrated in health technology assessments: an exploratory analysis of CADTH Common Drug Review. Res Involv Engagem 2, 21 (2016). DOI:10.1186/s40900-016-0036-9
Health technology assessment of drugs for rare diseases: insights, trends, and reasons for negative recommendations from the CADTH common drug review
Janoudi, G., Amegatse, W., McIntosh, B. et al. Health technology assessment of drugs for rare diseases: insights, trends, and reasons for negative recommendations from the CADTH common drug review. Orphanet J Rare Dis 11, 164 (2016). DOI:10.1186/s13023-016-0539-3
True North: Building Imaginary Worlds with the Revised Canadian (CADTH) Guidelines for Health Technology Assessment
Langley PC. True North: Building Imaginary Worlds with the Revised Canadian (CADTH) Guidelines for Health Technology Assessment. Inov Pharm. Vol. 8 No. 2 (2017) DOI:10.24926/iip.v8i2.514